B-lymphocyte alloantigens associated with systemic lupus erythematosus.

In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med (1987) 2.93

Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct from the HLA-DR antigen. Proc Natl Acad Sci U S A (1981) 2.86

Studies of immune functions of patients with systemic lupus erythematosus. Complement-dependent immunoglobulin M anti-thymus-derived cell antibodies preferentially inactivate suppressor cells. J Clin Invest (1979) 1.87

Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med (1983) 1.79

Disease associations of the Ia-like human alloantigens. Contrasting patterns in rheumatoid arthritis and systemic lupus erythematosus. J Exp Med (1978) 1.71

Polymorphism and complexity of the human DC and murine I-A alpha chain genes. EMBO J (1983) 1.50

Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet (2012) 1.41

DR and non-DR Ia allotypes are associated with susceptibility to coeliac disease. Gut (1985) 1.35

Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun (2011) 1.11

Impaired fc-mediated mononuclear phagocyte system clearance in HLA-DR2 and MT1-positive healthy young adults. J Exp Med (1983) 1.09

Narcolepsy. J Clin Neurophysiol (1990) 1.07

Animal models of human systemic lupus erythematosus. Yale J Biol Med (1979) 1.02

Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant. J Clin Invest (1991) 1.00

Neonatal lupus erythematosus: five new cases with HLA typing. Can Med Assoc J (1983) 0.95

T lymphocyte activation in systemic lupus erythematosus analysed by proliferative response to nucleoplasmic proteins on nitrocellulose immunoblots. Clin Exp Immunol (1989) 0.91

HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens. Ann Rheum Dis (1987) 0.90

Analysis of tumor necrosis factor promoter responses to ultraviolet light. J Clin Invest (1994) 0.88

Association of HLA-DRw2 with autoimmune thrombocytopenic purpura. J Clin Invest (1979) 0.85

Iridocyclitis in black Americans: association with HLA B8 suggests an autoimmune aetiology. Br J Ophthalmol (1981) 0.83

Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus. Clin Dev Immunol (2012) 0.83

Familial systemic lupus erythematosus: the role of genetic and environmental factors. Ann Rheum Dis (2002) 0.81

Family distribution of anti-F(ab')2 antibodies in relatives of patients with systemic lupus erythematosus. Clin Exp Immunol (1985) 0.81

Association between HLA-DR antigens and rheumatoid arthritis in Arabs. Ann Rheum Dis (1990) 0.81

Autoantibodies against eukaryotic protein L7 in patients suffering from systemic lupus erythematosus and progressive systemic sclerosis: frequency and correlation with clinical, serological and genetic parameters. The SLE Study Group. Clin Exp Immunol (1995) 0.80

Concomitant systemic lupus erythematosus and ankylosing spondylitis. Ann Rheum Dis (1990) 0.80

HLA antigens in Malay patients with systemic lupus erythematosus: association with clinical and autoantibody expression. Korean J Intern Med (2001) 0.79

The Yaa gene abrogates the major histocompatibility complex association of murine lupus in (NZB x BXSB)F1 hybrid mice. J Clin Invest (1994) 0.79

Human histocompatibility antigen associations in subacute cutaneous lupus erythematosus. J Clin Invest (1981) 0.78

Analysis of antigen specific T cell helper function in first degree relatives of patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1986) 0.78

The relationship between genetics and environment in the pathogenesis of rheumatic diseases. West J Med (1979) 0.77

Epistasis between the MHC and the RCA alpha block in primary Sjögren syndrome. Ann Rheum Dis (2007) 0.77

New approaches to treating systemic lupus erythematosus. West J Med (1987) 0.75

Rheumatic disease-a case of the soil and the seed. West J Med (1979) 0.75

Coexistence of ankylosing spondylitis and undifferentiated connective tissue disease. Clin Rheumatol (1998) 0.75

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 13.32

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49

Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum (1977) 8.55

Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med (1969) 6.16

Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 5.58

Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science (1992) 5.25

Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci U S A (1984) 5.15

Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68

Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63

A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01

The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol (1974) 3.98

Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81

X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J Exp Med (1975) 3.70

Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science (1982) 3.67

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (1996) 3.47

Epidermal Langerhans cells--a target for HTLV-III/LAV infection. J Invest Dermatol (1987) 3.41

EFFECT OF PETROLEUM OILS ON THE RESPIRATION OF BEAN LEAVES. Plant Physiol (1931) 3.33

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation (2001) 3.15

Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol (1978) 3.07

Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol (1991) 3.04

X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect. J Exp Med (1975) 3.03

Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03

Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02

The genetics of the immune response to a synthetic double-stranded RNA in a mutant CBA mouse strain. J Immunol (1973) 3.00

Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1978) 2.94

Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol (1980) 2.89

Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct from the HLA-DR antigen. Proc Natl Acad Sci U S A (1981) 2.86

Decline in suppressor T cell function with age in female NZB mice. J Immunol (1974) 2.79

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77

Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation (1998) 2.77

Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71

Structure of HLA antigens: amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations. Proc Natl Acad Sci U S A (1976) 2.71

How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum (1985) 2.68

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 2.68

Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation (1999) 2.59

Cerebral perfusion pressure: management protocol and clinical results. J Neurosurg (1995) 2.58

Detection of circulating immune complexes in pathological human sera. Lancet (1975) 2.51

Loss with age in NZB-W mice of thymic suppressor cells in the graft-vs-host reaction. J Immunol (1974) 2.45

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 2.38

Selective loss of suppressor cell function in New Zealand mice induced by NTA. J Immunol (1977) 2.38

Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med (1983) 2.38

The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.31

Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol (1981) 2.30

Antigen-specific human T lymphocyte clones: induction, antigen specificity, and MHC restriction of influenza virus-immune clones. J Immunol (1982) 2.30

Studies of immune functions of patients with systemic lupus erythematosus. I. Dysfunction of suppressor T-cell activity related to impaired generation of, rather than response to, suppressor cells. Arthritis Rheum (1979) 2.28

Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A (2000) 2.25

Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Medicine (Baltimore) (1973) 2.21

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17

DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice. J Immunol (1969) 2.13

Managanese oxidation by Sphaerotilus discophorus. J Bacteriol (1966) 2.12

Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation (1996) 2.10

Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest (1980) 2.06

Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med (1981) 2.05

Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE. Arthritis Rheum (1977) 2.03

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med (1993) 1.99

Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest (1993) 1.94

Genetic differences between primary and secondary sicca syndrome. N Engl J Med (1979) 1.93

Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med (1992) 1.90

Incidence of infection in systemic lupus erythematosus. Arthritis Rheum (1974) 1.89

Studies of immune functions of patients with systemic lupus erythematosus. Complement-dependent immunoglobulin M anti-thymus-derived cell antibodies preferentially inactivate suppressor cells. J Clin Invest (1979) 1.87

Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86

Effect of murine cytomegalovirus on the in vitro responses of T and B cells to mitogens. J Immunol (1976) 1.84

Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation (2001) 1.81

Characterization of a monoclonal antibody that defines an immunoregulatory T cell subset for immunoglobulin synthesis in humans. Proc Natl Acad Sci U S A (1980) 1.81

Multicentric reticulohistiocytosis: case report with immunohistochemical analysis and literature review. Arthritis Rheum (2000) 1.80

Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature (1989) 1.80

Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med (1979) 1.79

Detection of antigens specific for B-lymphoid cultured cell lines with human alloantisera. J Exp Med (1975) 1.76

End-stage renal disease and systemic lupus erythematosus. Am J Med (1996) 1.75

The cellular and genetic basis of murine lupus. Immunol Rev (1981) 1.75

Isolation and immunologic characterization of a human. B-lymphocyte-specific, cell surface antigen. J Exp Med (1976) 1.74

The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol (1972) 1.74

Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci U S A (1989) 1.73

Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation (1999) 1.70

Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med (1971) 1.70

HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol (1987) 1.69

The pathogenesis of autoimmunity in New Zealand mice. 3. Factors influencing the formation of anti-nucleic acid antibodies. Immunology (1971) 1.68

Hematologic aspects of systemic lupus erythematosus. Current concepts. Ann Intern Med (1977) 1.68

Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol (2001) 1.68

Purification of papain-solubilized histocompatibility antigens from a cultured human lymphoblastoid line, RPMI 4265. J Biol Chem (1975) 1.66

Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest (1984) 1.63

Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol (1995) 1.63

Autoimmunity--a perspective. Annu Rev Immunol (1983) 1.62

A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum (1982) 1.62

Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum (1973) 1.61

Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses. J Exp Med (1980) 1.61

NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med (1984) 1.61

Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA (1987) 1.60